Luther Corley, MD
Pulmonary Disease · Huntsville, ALNPI 1790861292
Payments from drug & device makers
Across 479 payments — averaging $180.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$73K
- Regeneron Healthcare Solutions, Inc.$4K
- Pulmonx Corporation$3K
- GSK$2K
- Insmed, Inc.$901
- AstraZeneca$884
- plus $4K from 30 others
What the payments were for
- Consulting fees$2,2503%
- Speaking & faculty fees$66,66977%
- Travel & lodging$5,3916%
- Food & beverage$11,99914%
- Education$1910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 99 | $72,985 |
| Regeneron Healthcare Solutions, Inc. | 44 | $3,760 |
| Pulmonx Corporation | 5 | $2,766 |
| GSK | 103 | $1,572 |
| Insmed, Inc. | 40 | $901 |
| AstraZeneca | 35 | $884 |
| Boehringer Ingelheim | 17 | $731 |
| Pfizer | 20 | $328 |
| Actelion Pharmaceuticals US, Inc. | 12 | $317 |
| Mylan Specialty L.p. | 13 | $253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $248 |
| Novartis | 13 | $238 |
| Amgen | 9 | $178 |
| Grifols USA, LLC | 7 | $174 |
| Pharming Healthcare, Inc. | 3 | $163 |
| Inspire Medical Systems, Inc. | 1 | $144 |
| Genentech USA, Inc. | 7 | $131 |
| Electromed, Inc. | 11 | $107 |
| Genentech, Inc. | 1 | $85 |
| Merck | 4 | $63 |
| Jazz Pharmaceuticals Inc. | 3 | $56 |
| Philips North America LLC | 3 | $53 |
| CSL Behring | 2 | $52 |
| Viatris Specialty LLC | 2 | $45 |
| Baxter Healthcare | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $27 |
| Harmony Biosciences LLC | 1 | $27 |
| Verona Pharma, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $20 |
| 3b Medical, Inc. | 1 | $18 |
| Gilead | 1 | $18 |
| Bayer | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Inogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$73,550
- ZEPHYR ENDOBRONCHIAL VALVE$2,748
- CHARTIS CATHETER$273
- ZEPHYR DELIVERY CATHETER$273
- PULMONX CHARTIS TABLET CONSOLE$273
- Inspire$144
- RUCONEST$129
- BREZTRI AEROSPHERE$125
- UPTRAVI$121
- OPSUMIT$121
- AIRSUPRA$115
- BREZTRI$115
- TEZSPIRE$115
- FASENRA$115
How this compares
$86,499 in reported general payments places this provider in the 90th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 104 | $401,391 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 374 | $363,929 |
| XolairOmalizumab | 71 | $178,559 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 176 | $126,635 |
| OfevNintedanib Esylate | 14 | $109,041 |
| Breo ElliptaFluticasone/Vilanterol | 227 | $106,796 |
| NucalaMepolizumab | 27 | $92,947 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 79 | $58,935 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 178 | $46,826 |
| Spiriva RespimatTiotropium Bromide | 47 | $38,397 |
| SymbicortBudesonide/Formoterol Fumarate | 114 | $37,063 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 54 | $33,404 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $26,600 |
| Advair HfaFluticasone Propion/Salmeterol | 52 | $25,062 |
| Arnuity ElliptaFluticasone Furoate | 89 | $24,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta | $1,572 | $670,500852 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $731 | $207,441151 claims |
| Genentech, Inc.Xolair | $85 | $178,55971 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $884 | $163,699290 claims |
| PfizerEliquis | $328 | $21,30135 claims |
| MerckDulera | $63 | $17,45937 claims |
| Johnson & JohnsonXarelto | $14 | $15,89215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Huntsville
- Roshen MathewHuntsville$19K
- Murthy VuppalaHuntsville$16K
- Richard SneeringerHuntsville$14K
- Misbahuddin SiddiquiHuntsville$12K
- Saketh Palasamudram ShekarHuntsville$11K
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Jan WestermanJasper$834K
- Bryan GarciaBirmingham$606K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.